OncoQuest, in partnership with a China-based global
pharmaceutical company, has launched a new venture in the

Onco-Immunology space

The Company has assembled several bioactive technologies, including human and xenotypic monoclonal antibodies of the IgG and IgE class that can induce tumor specific immunity and enhance clinical outcome. Several of the lead components have clinical track records and extensive development dossiers that can be exploited to be integral to combinatorial immunooncology treatment strategies.


OncoQuest is currently conducting a series of phase I/II combinatorial clinical studies in several cancer indications, notably pancreatic and ovarian cancer, to identify an optimal design for a product registration trial. The company firmly believes that based on preclinical data that the coordinated addition of an immune adjuvant and a checkpoint inhibitor may well raise the induced immunity to a new level of clinical significance; expediting clinical development strategies, permitting study in more advanced disease, and in fact raising the bar of performance that would otherwise not be achieved with the use of a checkpoint inhibition alone.  



Oncoquest Treatments

Recent News:


Feb 12, 2018

OncoQuest to Present at BIO CEO & Investor Conference   

Feb 06, 2018

OncoQuest Completes US $6 Million Private Placement  

Nov 14, 2017

OncoQuest Announces Presentation of Pre-Clinical Data from its IgE Based Immunotherapy Platform Technology at the 32nd Annual Society for Immunotherapy of Cancer (SITC)  

Nov 07, 2017

OncoQuest Announces Presentation of Translational Immunology Data from Phase 2 Clinical Study Examining Oregovomab in Combination with Chemotherapy in Front Line Ovarian Cancer at the International Meeting of European Society of Gynaecological Oncology (ESGO) 2017  

Oct 26, 2017

OncoQuest Announces Collaboration with TESARO in Recurrent Ovarian Cancer Setting  

July 26, 2017

First Patient Enrolled in OncoQuest’s Phase 1/2 Study Combining Oregovomab with Hiltonol® in Recurrent Ovarian Cancer  

June 27, 2017

OncoQuest Appoints Senior Biotech Investment Banker Hany Awadalla as Senior Vice President and Chief Financial Officer  

May 24, 2017

OncoQuest to Present Oregovomab Phase II Interim Clinical Results for Front Line Treatment of Ovarian Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

Edmonton Journal Article, December 8, 2016

May 9, 2017

OncoQuest Announces Enrollment of First Patient in Phase 1/2 Clinical Study Using Combination of Oregovomab with Checkpoint Inhibitor Nivolumab in Recurrent Ovarian Cancer

December 7, 2016

OncoQuest Initiates Commercial Scale Oregovomab Manufacturing Program for Treatment of Ovarian Cancer

November 29, 2016

OncoQuest Announces Positive Interim Results from Its Phase 2b Clinical Study